| Company Name: |
ChemShuttle, Inc.
|
| Tel: |
0510-83588313-811 18800520310 |
| Email: |
sales@chemshuttle.com |
| Products Intro: |
Product Name:4-(4-(2,4-dibromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine
CAS:1621375-32-3
Purity:95% Package:5mg;25mg;100mg;500mg;1g;5g;10g;25g;50g;100g;250g;500g;kg…
|
4-(4-(4,5-dibromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine manufacturers
- VPC-14449
-
- $269.00 / 25mg
-
2025-11-10
- CAS:1621375-32-3
- Min. Order:
- Purity: 99.56%
- Supply Ability: 10g
|
| | 4-(4-(4,5-dibromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine Basic information |
| | 4-(4-(4,5-dibromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine Chemical Properties |
| Boiling point | 551.4±60.0 °C(Predicted) | | density | 2.12±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 125 mg/mL (317.19 mM; Need ultrasonic) | | form | Solid | | pka | 2.01±0.50(Predicted) | | color | White to off-white |
| | 4-(4-(4,5-dibromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine Usage And Synthesis |
| Uses | VPC-14449 is a potent and selective inhibitor of the DNA-binding domain of the androgen receptor (AR-DBD), with IC50 of 0.34 μM for full-length human AR. VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin. VPC-14449 can be used for the research of prostate cancer[1][2]. | | Biological Activity | VPC-14449 is a potent and selective inhibitor of the DNA-binding domain of the androgen receptor (AR-DBD), with IC50 of 0.34 μM for full-length human AR. VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin. VPC-14449 can be used for the research of prostate cancer[1][2].
VPC-14449 (0.01-100 μM; 24 h) inhibits AR-transcriptional activity and cell viability in LNCaP, C4-2, MR49F, and 22Rv1 cells[2].VPC-14449 (0.01-100 μM; 24 h) dose-dependently inhibits the transiently expressed full-length human AR in PC3 cells (IC50=0.34 μM) without affecting AR protein expression[1].
VPC-14449 (100 mg/kg; i.p. twice daily for 4 weeks) reduces tumor volume and abolishes PSA production with no decrease in body weight over a total duration 4 weeks in LNCaP xenograft model[1]. | | in vivo | VPC-14449 (100 mg/kg; i.p. twice daily for 4 weeks) reduces tumor volume and abolishes PSA production with no decrease in body weight over a total duration 4 weeks in LNCaP xenograft model[1]. | Animal Model: | Nude mice (Harlan Sprague-Dawley; 25-31 g; 6-8 weeks) were subcutaneously inoculated with LNCaP cells and castrated[1] | | Dosage: | 100 mg/kg | | Administration: | I.p. twice daily for 4 weeks | | Result: | Suppressed LNCaP tumor volume and blocked serum PSA production. |
| | References | [1]. Dalal K, et, al. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem. 2014 Sep 19;289(38):26417-26429. [2]. Dalal K, et, al. Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions. Mol Cancer Ther. 2017 Oct;16(10):2281-2291. |
| | 4-(4-(4,5-dibromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine Preparation Products And Raw materials |
|